SEC Form 4 · accession 0001628280-26-059444

Arcutis Biotherapeutics, Inc. · ARQT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 27, 2026

Accepted (ET)

Aug 28, 2026 · 5:40 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001787306

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 27, 2026	M	11,148	$7.51	A	34,674	D
Common Stock^F2	Aug 27, 2026	S	11,148	$25.0294	D	23,526	D
Common Stock	Aug 27, 2026	M	27,052	$8.63	A	50,578	D
Common Stock^F2	Aug 27, 2026	S	27,052	$25.0294	D	23,526	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$7.51	Aug 27, 2026	M	11,148	D	—	May 31, 2033	Common Stock	11,148	0	D
Stock Option (right to buy)^F4	$8.63	Aug 27, 2026	M	27,052	D	—	Jun 14, 2034	Common Stock	27,052	0	D

F1The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F4The option is fully vested.